Ironwood Pharmaceuticals
IRWD
155 hedge funds and large institutions have $2.19B invested in Ironwood Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 41 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
41% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 41
22% more capital invested
Capital invested by funds: $1.79B → $2.19B (+$397M)
7% more funds holding
Funds holding: 145 → 155 (+10)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less call options, than puts
Call options by funds: $8.35M | Put options by funds: $9.45M
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$49.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.7M |
| 3 |
Goldman Sachs
New York
|
+$13.8M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$9.52M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$7.65M |
Top Sellers
| 1 |
BM
Bridger Management
New York
|
-$27.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$22.8M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$14.4M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$14.1M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$13.5M |
IRWD Hedge Fund Activity: Q3 2016 in Review
155 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2016, worth a combined $2.19B — up 22% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new IRWD positions and 18 closed out — a net gain of 10 holders — while 58 added to existing stakes and 41 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $49.2M. The largest seller was Bridger Management, cutting an estimated $27.8M.
- 155 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2016, up from 145 in Q2 2016.
- Funds reported $2.19B of Ironwood Pharmaceuticals stock for Q3 2016, up 22% quarter-over-quarter.
- 28 funds opened new Ironwood Pharmaceuticals positions in Q3 2016 and 18 closed out, a net change of +10 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2016 was Adage Capital Partners, an estimated $49.2M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2016 was Bridger Management, an estimated $27.8M sold.
Based on aggregated 13F filings for Q3 2016.